Research
Hormonal
Pharmacotherapy (Orlistat, Lorcaserin, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide) adds 2.5 to 8.9 kg of mean weight loss compared to placebo when used as an adjunct to lifestyle intervention.
If lifestyle changes alone aren't enough, FDA-approved medications can help. These drugs work by reducing hunger or blocking fat absorption. They are meant for long-term use, not quick fixes. Consult a doctor to see if you are a candidate based on your BMI and health history.
StrongSupportsHIGH confidence
The addition of these medications to lifestyle intervention increases mean weight loss by 2.5 to 8.9 kg compared with placebo.
Why this rating
Based on FDA approvals and multiple RCTs cited in the review.
Source
Management of Obesity
Naji Alamuddin et al. · Journal of Clinical Oncology · 2016
DOI 10.1200/jco.2016.66.8806
narrative_reviewCited 62×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Comprehensive lifestyle interventions consisting of diet, physical activity, and behavior therapy produce clinically meaningful weight loss (6-8% of initial body weight) and reduce the risk of type 2 diabetes, provided a caloric deficit of at least 500 kcal/day is maintained.Strong
- Bariatric surgery (Roux-en-Y gastric bypass, sleeve gastrectomy) yields long-term (>3 years) weight reductions of ≥ 20% of initial body weight and decreases morbidity and potentially mortality in patients with severe obesity.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →